Vasopressin regulatory status
Current status of Vasopressin in the United States: FDA approved. In sport: WADA status unclear. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Vasopressin?
Regulatory: FDA approvedWADA: WADA status unclearVerified: Verified Sep 23, 2026
- FDA and compounding
- Vasopressin injection was marketed for decades as an unapproved drug and became FDA approved as Vasostrict in April 2014 for vasodilatory shock; generic vasopressin injections were approved beginning in 2021. Hospital pharmacies may prepare diluted infusions from approved vials. Vasopressin sold online for intranasal use as a cognitive or social enhancer is not an approved product and is not compounded by licensed pharmacies for that purpose.
- WADA
- WADA status unclear
- Access path
- Administered intravenously in hospitals and intensive care units; not dispensed to patients.
- Products sold online for intranasal use are unapproved and not lawful for human use.
Full Vasopressin page: evidence, dosing in the literature, and sources
How has the status of Vasopressin changed over time?
No dated regulatory event has been recorded for Vasopressin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Vasopressin and the source of each dated event.